ReviewCurrent opinion in microbiology2017
The mucormycete-host interface.
Review in Current opinion in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Infection metallomics of pulmonary mucormycosis: multi-omics study of siderophore secretion, neutrophil recruitment, and lipid remodeling in rat lungs.Analytical and bioanalytical chemistry · 2026Article
- Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis.Journal of fungi (Basel, Switzerland) · 2026Article
- Light restores sporulation in Rhizopus microsporus cured of its endosymbionts, unveiling their role in fitness and virulence.The ISME journal · 2026Article
- Three hydrophobic surface binding a proteins link surface hydrophobicity to sporulation, biofilm formation, and host interaction inFrontiers in cellular and infection microbiology · 2026Article
- Transcriptomic and proteomic profiling of pulmonary mucormycosis reveals a failed activation of host immune response.Frontiers in immunology · 2026Article
- The Unnoticed Threat: Clinical Characteristics, Risk Factors, and Outcome of Mucormycosis in Solid Organ Transplantation.Journal of fungi (Basel, Switzerland) · 2025Review
- [Characteristics of mucormycosis in adult acute leukemia: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Review
- Mucormycosis in 2023: an update on pathogenesis and management.Frontiers in cellular and infection microbiology · 2023Review
- Review
- Mucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- A bacterial endosymbiont of the fungus Rhizopus microsporus drives phagocyte evasion and opportunistic virulence.Current biology : CB · 2022Article
- Multidisciplinary approach in diagnosis and treatment of COVID-19-associated mucormycosis: a description of current reports.The Egyptian journal of internal medicine · 2022Review
- Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes.Journal of fungi (Basel, Switzerland) · 2021Review
- Article
- DNA Methylation on N6-Adenine Regulates the Hyphal Development during Dimorphism in the Early-Diverging FungusJournal of fungi (Basel, Switzerland) · 2021Article
- Mucormycosis in Indian COVID-19 Patients: Insight into Its Patho-Genesis, Clinical Manifestation, and Management Strategies.Antibiotics (Basel, Switzerland) · 2021Review
- Current Understanding in the Pathophysiology of SARS-CoV-2-Associated Rhino-Orbito-Cerebral Mucormycosis: A Comprehensive Review.Journal of maxillofacial and oral surgery · 2021Review
- The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Medical mycology case reports · 2021Article
- EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion.Cell reports · 2021Article
- Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Mucormycosis is a fungal infection with fulminant angioinvasion leading to high morbidity and mortality in susceptible individuals. The major predisposing conditions are uncontrolled diabetes, neutropenia, malignancies, receipt of a transplant and traumatic injury [1]. Over the past decade, mucormycosis has become an emerging fungal infection due to the increase in patient groups presenting with these pre-disposing conditions and our medical advances in diagnosing the infection [2-4]. Yet, we currently lack clinical interventions to treat mucormycosis effectively. This in turn is due to a lack of understanding of mucormycosis pathogenesis. Here, we discuss our current understanding of selected aspects of interactions at the mucormycete-host interface. We will highlight open questions that might guide future research directions for investigations into the pathogenesis of mucormycosis and potential innovative therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.